Stay updated with breaking news from Abbvie imbruvica. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AbbVie Lifts Profit Forecast After Skyrizi Sales Beat Expectations usnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from usnews.com Daily Mail and Mail on Sunday newspapers.
(Reuters) -AbbVie raised its annual profit forecast on Friday after strong sales of its immunology drug Skyrizi and cancer drug Imbruvica helped the company beat Wall Street estimates for the first quarter. The company now expects adjusted profit of between $11.13 and $11.33 per share for this year, compared with $10.97 to $11.17 estimated earlier. Analysts on average expect annual profit of $11.10 per share, according to LSEG data. ....
AbbVie raised its annual profit forecast on Friday after strong sales of its immunology drug Skyrizi and cancer drug Imbruvica helped the company beat Wall Street estimates for the first quarter. . ....
Oncternal Therapeutics reports patient death in CAR-T dose-escalation study fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Amgen, Regeneron, AbbVie join Lilly, Novo with market cap gains fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.